ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Educational Symposium

B-Cell Therapy over a Patient's Lifetime: When and Where to Deploy It in Lupus Nephritis and Membranous Nephropathy

October 22, 2026 | 12:45 PM - 01:45 PM

Location: Centennial Ballroom D, Hyatt Regency Denver

Session Description

B cells play a pivotal role in autoimmune kidney diseases through their contributions to autoantibody production and loss of immune tolerance. In lupus nephritis and membranous nephropathy, antibody-mediated injury drives inflammation, kidney damage, and progressive loss of function.

This symposium explores the immunopathogenesis of these disorders and the expanding role of B-cell-targeted therapies. Experts review the mechanisms of action, clinical trial evidence, and practical application of emerging and established therapies, including their use in induction, maintenance, and relapse management. Similarities and differences in treatment approaches between lupus nephritis and membranous nephropathy are highlighted, providing participants with a contemporary framework for optimizing patient outcomes.

Doors open around 12:30 p.m. Seating is limited and available on a first-come, first-served basis to fully paid Annual Meeting participants. When a room reaches capacity, ASN will close the room, and no other participants will be allowed to enter, regardless of how many exit.

Support is provided by an educational grant from Genentech, a member of the Roche Group.

Learning Objective(s)

  • Describe the pathophysiology of autoimmunity in lupus nephritis and membranous nephropathy, including the role of B cells
  • Compare various B-cell therapies
  • Explain when B-cell therapies should be used for lupus nephritis and membranous nephropathy during induction, maintenance, and relapse

Learning Pathway(s)

  • Glomerular Diseases
  • Pharmacology

Moderator

Presentations